QSAM Biosciences
Treating cancer in children and adults with targeted radiotherapeutics.
Launch date
Employees
Market cap
€33.5m
Enterprise valuation
€33m (Public information from May 2024)
Share price
$8.3 QSAM
Austin Texas (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | <1m | - | - | - | - |
| EBITDA | - | - | (<1m) | (4.5m) | (11.0m) | (5.5m) | (4.0m) |
| % EBITDA margin | - | - | (11 %) | - | - | - | - |
| Profit | - | - | (<1m) | (4.9m) | (12.0m) | (5.5m) | (4.4m) |
| % profit margin | - | - | (74 %) | - | - | - | - |
| EV / revenue | - | - | 4.3x | - | - | - | - |
| EV / EBITDA | - | - | -37.7x | -2.9x | -1.0x | -1.6x | -5.1x |
| R&D budget | - | - | - | <1m | <1m | 1.0m | 1.2m |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
* | $33.1m | Acquisition | |
| Total Funding | - | ||